Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Tranexamic Acid vs PRP for Melasma
NCT05884151Phase 1Completed
- Sponsor
- Combined Military Hospital Abbottabad
- Start
- Nov 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules, Adipose-derived MSCs, Bone Marrow MSCs
- Countries
- 1
01
Overview
Phase 1, randomised trial of tranexamic acid and platelet-rich plasma in melasma (2 arms), sponsored by Combined Military Hospital Abbottabad. Primary endpoint: Melasma Severity Index at 24 weeks. Started Nov 2022; status: completed.
02
Drugs
tranexamic acidplatelet-rich plasma
03
Conditions
melasma
Beyond the preview
Go deeper on NCT05884151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05884151.